<DOC>
	<DOCNO>NCT01502241</DOCNO>
	<brief_summary>The study aim optimize treatment elderly subject ( &gt; 65 ) anaplastic astrocytoma glioblastoma . Current treatment policy tend palliative . There consensus radical surgery . Involved-field radiotherapy treatment likely accept apart supportive palliative measure . The role chemotherapy barely define . Study data available date suggest patient population would benefit combined radiochemotherapy . The aim study verify hypothesis first-line chemotherapy one week on/one week temozolomide inferior extended-field radiotherapy first-line treatment anaplastic astrocytoma glioblastoma elderly ( &gt; 65 age group ) . The primary endpoint median survival , life expectancy limit several month . Secondary endpoint response rate arm ( CR , PR , MacDonald et al . 1990 ) , median progression-free survival , 1-year 2-year survival rate , definition MGMT molecular genetic prognostic predictive marker , quality life . Theoretically , possible preserve quality life first-line chemotherapy arm study .</brief_summary>
	<brief_title>Phase III Trial Primary Radio- Chemotherapy Malignant Astrocytoma Elderly</brief_title>
	<detailed_description>This study prospective , randomized Phase III intervention study . Following histological documentation diagnosis biopsy resection anaplastic astrocytoma glioblastoma , patient randomize either receive postoperative extended-field radiotherapy ( arm A ) receive postoperative chemotherapy temozolomide ( arm B ) . Randomization do sit CRO , Alcedis GmbH . For patient intend participate study , procedure follow : - Request reference neuropathological review brain tumor reference center Bonn ( Prof. Dr. G. Reifenberger ) local neuropathology department . This review need present randomization anaplastic astrocytoma glioblastoma case eligible - Contact : Prof. Dr. W. Wick , Dep . Neurooncology , National Center Tumor Diseases Neurology Clinic , University Heidelberg , wolfgang.wick @ med.uni-heidelberg.de CRO : Alcedis , Giessen Alcedis GmbH , I . Helm , Winchester Str . 2 , 35394 Gießen , Tel . : 0641 944360 , Fax : 0641 94436 70 , E-mail : ihe @ alcedis.de - Provide write confirmation patient sign ethic committee-approved consent form - Submit registration form copy EORTC-QLQ give Annexes In subject progressive recurrent disease , investigate site verify whether specific tumor treatment justify . If yes , chemotherapy temozolomide recommend arm A , possibly surgery . Subjects arm B receive radiotherapy , possible surgery . As all-cause mortality primary endpoint , therapeutic measure follow first-line therapy document . If study treatment discontinue ( first-line therapy ) progressive disease progression occur completion study treatment , pertinent image submit reference center neuroradiology Tübingen reference review . The treatment modality employ study chemotherapeutic radiotherapeutic procedure license Federal Republic Germany use human subject . Temozolomide currently license treat subject recurrent disease since 2006 newly diagnose glioblastoma together radiotherapy . The time allot individual treatment section 6 week radiotherapy , chemotherapy continue progression unacceptable adverse effect occur . The precise chemotherapy sequence show protocol . The criterion withdrawal study define protocol . Four year period schedule recruiting patient .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>Histologically confirm supratentorial anaplastic astrocytoma glioblastoma Age &gt; 65 Karnofsky performance score &gt; 60 % Neutrophilic granulocyte count &gt; 1500/µl Platelet count &gt; 100 000/µl Hemoglobin &gt; 10 g/dl Serum creatinine &lt; 1.5 time lab 's upper normal limit AST ALT &lt; 3 time lab 's upper normal limit Alkaline phosphatase &lt; 3 time lab 's upper normal limit No previous systemic chemotherapy No previous radiotherapy brain Written consent Serious medical neurological condition poor prognosis HIV infection Second cancer require radiotherapy chemotherapy ( contact study coordinat necessary ) Hypersensitivity temozolomide Conditions associate regular vomiting might affect oral administration drug Psychological , familial , social geographical circumstance major implication compliance study visit schedule Patient take part intervention study within month start study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>elderly</keyword>
	<keyword>brain tumor</keyword>
	<keyword>MGMT</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>Newly diagnose</keyword>
	<keyword>patient &gt; 65 year</keyword>
</DOC>